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There has been a great level of enthusiasm to down-
regulate overactive N-methyl-D-aspartate (NMDA)
receptors to protect neurons from excitotoxicity.
NMDA receptors play pivotal roles in basic brain
development and functions as well as in neurolog-
ical disorders and diseases. However, mechanistic
understanding of antagonism in NMDA receptors
is limited due to complete lack of antagonist-bound
structures for the L-glutamate-binding GluN2
subunits. Here, we report the crystal structures
of GluN1/GluN2A NMDA receptor ligand-bind-
ing domain (LBD) heterodimers in complex with
GluN1- and GluN2-targeting antagonists. The crystal
structures reveal that the antagonists, D-()-2-
amino-5-phosphonopentanoic acid (D-AP5) and 1-
(phenanthrene-2-carbonyl)piperazine-2,3-dicarbox-
ylic acid (PPDA), have discrete binding modes and
mechanisms for opening of the bilobed architecture
of GluN2A LBD compared to the agonist-bound
form. The current study shows distinct ways by
which the conformations of NMDA receptor LBDs
may be controlled and coupled to receptor inhibition
and provides possible strategies to develop thera-
peutic compounds with higher subtype-specificity.
INTRODUCTION
Situated in the midst of the synaptic transmission paradigm,
N-methyl-D-aspartate (NMDA) receptors have long been studied
from the perspectives of both basic neuroscience and clinical
science. These receptors belong to the large family of ionotropic
glutamate receptors (iGluRs), which bind the neurotransmitter
L-glutamate and meditate the majority of the fast excitatory
neurotransmission in the mammalian brain (Kandel et al., 1995;
Traynelis et al., 2010). Pharmacological identification of those
receptors have been led by a key finding that NMDA induces cur-
rent formation in neurons (Watkins and Evans, 1981) followed by
the important discovery that the NMDA-induced current can be
specifically inhibited by antagonists such as D-a-aminoadipate
and D-()-2-amino-5-phosphonopentanoic acid (D-AP5) (Evans366 Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc.et al., 1982). Thus, the discovery of D-AP5 played a critical role in
confirming the presence of iGluRs in neurons.
NMDA receptors are obligatory hetero-tetramers composed
of eight splicing variants of GluN1 (1–4 a or b) and GluN2 (A–D)
and/or GluN3 (A–B) of which GluN1 and GluN3 bind glycine
and GluN2 binds L-glutamate and NMDA (Benveniste and
Mayer, 1991; Clements and Westbrook, 1991). Consistent with
the hetero-tetrameric assembly, activation of GluN1/GluN2
NMDA receptors requires concurrent binding of glycine and
L-glutamate (Johnson and Ascher, 1987). Combinations of
different GluN2 subunits (A–D) with the splicing variants of
GluN1 subunits result in formation of ion channels with distinct
spatiotemporal expression patterns (Monyer et al., 1994) and
pharmacological and electrophysiological properties (Vicini
et al., 1998). Subtype-specific targeting of NMDA receptors
has been an important challenge especially from the clinical
point of view as dysfunctional NMDA receptors are implicated
in various neurological disorders and injuries including depres-
sion, schizophrenia, Alzheimer’s and Parkinson’s disease, and
stroke (Paoletti, 2011). Decades of efforts have led to identifica-
tion of allosteric compounds with subtype-selectivity including
ifenprodil (GluN2B) (Gallagher et al., 1996), TCN201 (GluN2A)
(Bettini et al., 2010), QNZ46 (GluN2D) (Acker et al., 2013; Mosley
et al., 2010), and CIQ (GluN2C/D) (Mullasseril et al., 2010). Of
these, ifenprodil and its analogs have been used most exten-
sively and successfully in neuroscience research, while others
have only been used with minimal success to date. For example,
it is difficult to specifically inhibit GluN2A in neurons with TCN201
because its effect is robustly altered at different glycine concen-
trations (Hansen et al., 2012). A phenanthrene-based competi-
tive antagonist with moderate selectivity for GluN2C/D over
GluN2A/B, such as 1-(phenanthrene-2-carbonyl) piperazine-
2,3-dicarboxylic acid (PPDA), was identified more than a decade
after D-AP5 (Feng et al., 2004). However, in general, competitive
antagonists with high degree of subtype-specificity have been
slow to develop due to complete lack of structural information
that shows binding modes of antagonists at the GluN2 subunits.
Structural studies on iGluRs in the past 15 years have led to
understanding of subunit assembly, ligand recognition, and reg-
ulatory mechanism of gating at the molecular level (Mayer,
2011). Thus far, the most advanced subfamily members with
respect to structural studies are a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and kainate receptors with
the intact tetrameric structures obtainedby X-ray crystallography
and electron microscopy, respectively (Schauder et al., 2013;
Figure 1. Domain Organization of NMDA
Receptor Subunits and Ligands
(A) NMDA receptor subunits are modular proteins
composed of an amino terminal domain (ATD), a
ligand-binding domain (LBD), a transmembrane
domain (TMD), and a cytosolic domain (CTD). Their
modular domains are oriented such that the N ter-
minus (NT) and the C terminus (CT) are located at the
extracellular and cytoplasmic regions, respectively.
In this study, LBDs from GluN1 and GluN2A are
isolated (scissors) by tethering two peptide frag-
ments between TMD M1 and M3 by a Gly-Thr
dipeptide linker (dashed line).
(B) Ligands for GluN1 and GluN2 subunits. Glycine
and 5,7-dichlorokynurenic acid (DCKA) are an
agonist and an antagonist, respectively, for GluN1.
L-glutamate and NMDA are agonists for GluN2
LBD. D-()-2-amino-5-phosphonopentanoic acid
(D-AP5) and 1-(phenanthrene-2-carbonyl)pipera-
zine-2,3-dicarboxylic acid (PPDA) with distinct
chemical structures both act as competitive antag-
onists at the GluN2 LBD.
See also Figures S1 and S5.
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Structures of Antagonist-Bound NMDA ReceptorsSobolevsky et al., 2009). Studies on NMDA receptors have been
limited to the extracellular domains, including an amino terminal
domain (ATD) (Farina et al., 2011; Karakas et al., 2009, 2011)
and a ligand-binding domain (LBD) of GluN1 (Furukawa and
Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005; Yao
et al., 2013), GluN2 subunits (Furukawa et al., 2005; Vance
et al., 2011), and GluN3 subunits (Yao et al., 2008). Furthermore,
the structural information of the antagonist-bound form of NMDA
receptors is restricted to that of GluN1 LBD (Furukawa and
Gouaux, 2003; Inanobe et al., 2005). Thus, despite the historical
importance, the molecular mechanism underlying inhibition of
NMDA receptors by D-AP5 at GluN2 LBD has remained enig-
matic. Moreover, it is not known how phenanthrene-based com-
pounds such asPPDA (Fenget al., 2004)with a drastically distinct
chemical structure fromD-AP5can function asan antagonistwith
some degree of subtype-specificity (Figure 1). The limited under-
standing of this neuropharmacological problem is largely due to
technical difficulties associatedwith crystallization of the antago-
nist-bound GluN2 subunit. In this study, we overcome the tech-
nical challenge and report crystal structures of heterodimeric
GluN1/GluN2ALBD incomplexwith four combinationsof ligands:
glycine/L-glutamate, glycine/D-AP5, glycine/()-PPDA, and 5,7-
dichlorokynurenic acid (DCKA)/L-glutamate. The high resolution
crystal structures along with site-directed mutagenesis and
electrophysiology pinpoint the elements necessary for binding
of ligands with distinct chemical nature. Comparison of the four
crystal structures shows the pattern of global protein conforma-
tional alterations in the context of the GluN1/GluN2A heteromer,
thereby showing the plausible mechanism for antagonism.
RESULTS
Structural Study on Antagonist-NMDA Receptor
Complex
To capture the structural representation of competitive antago-
nism in NMDA receptors, we sought to crystallize the GluN1/GluN2A LBD heterodimer in complex with antagonists for
GluN1, DCKA, GluN2, D-AP5, and PPDA (Figure 1). Based on
the previous work, it is well established that iGluRs are arranged
as a dimer of two dimers at the extracellular domains (Mayer,
2011) and that the NMDA receptor LBDs form GluN1-GluN2
heterodimers (Furukawa et al., 2005). To date, there are several
antagonist-bound structures in the context of GluN1 LBD (Furu-
kawa and Gouaux, 2003; Inanobe et al., 2005), but not in the
context of the physiologically relevant GluN1/GluN2A LBD heter-
odimer. Furthermore, no antagonist-bound structure of LBDs for
any GluN2 subunits is presently available due to difficulties in
crystallizing the antagonist-receptor complex. Thus, instead of
cocrystallizing the receptor-ligand complexes, we have sought
to take an alternative approach involving soaking of crystals of
GluN1/GluN2A LBDs in complex with glycine and L-glutamate
(GluN1/GluN2A LBD-gly/glu) (Furukawa et al., 2005) against
the crystallization buffer containing DCKA and L-glutamate
(DCKA/glu), glycine and D-AP5 (gly/D-AP5), and glycine and
the racemic mixture of (+)- and ()-PPDA enantiomers (gly/
PPDA).
The GluN1/GluN2A LBD-gly/glu crystals obtained in the previ-
ously published condition had a limited size (15 mm3 15 mm3
100 mm)with radiation decay that disallowed collection of a com-
plete data set (Furukawa et al., 2005). Soaking of those small
crystals against antagonist containing solutions resulted in
severe cracking and prevented diffraction analysis. Thus, we first
screened for the crystallization condition for GluN1/GluN2A
LBD-gly/glu and found that the vapor diffusion method in the
presence of PEG2000 MME at pH 7 and 17C (see Experimental
Procedures) produced substantially larger crystals (50 mm 3
50 mm 3 500 mm) than the one previously reported. Importantly,
these crystals withstood soaking against the antagonist contain-
ing solutions and provided complete X-ray diffraction data sets
at high resolution for all of the above states (Table S1 available
online). Extensive soaking of the GluN1/GluN2A LBD-gly/glu
crystals against a buffer containing D-AP5 (1 mM), PPDANeuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc. 367
Figure 2. Structures of GluN1/GluN2A LBDs
in Complex with Various Ligands
(A–D) The four crystal structures of GluN1/GluN2A
LBDs in complex with glycine (Gly; gray sphere)
and L-glutamate (Glu; green sphere) (A), DCKA
(blue sphere) and L-glutamate (B), glycine and
D-AP5 (yellow sphere; C), and glycine and PPDA
(cyan sphere; D). The GluN1 and GluN2A LBDs
exist as a heterodimer in the asymmetric unit of
the orthorhombic crystals obtained in this study
(Table S1). The structures are oriented so that the
N-terminal ends (NT) from both GluN1 andGluN2A
face top of this figure. GluN1 and GluN2A LBDs
are shaped like bilobed clamshells composed of
upper (D1) and lower (D2) domains colored green
and orange, respectively, in GluN1 and blue and
magenta, respectively, in GluN2A. All of the li-
gands studied here bind at the D1-D2 interface.
Sticks represent three disulfide bonds conserved
among the NMDA receptor family members. The
spheres at the bottom of the structures represent
the Ca of the glycine residue in the Gly-Thr
dipeptide linker, where loops leading to the M1
TMDand from theM3 TMDwould be located in the
full-length receptors.
See also Figures S1 and S2.
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Structures of Antagonist-Bound NMDA Receptors(0.1 mM), or DCKA (1 mM) as described in the Experimental Pro-
cedures resulted in large alterations in the cell unit dimensions
but with no change in the space group (Table S1). Structures
for the antagonist-bound GluN1/GluN2A LBDs were solved
by molecular replacement (MR) using the following structural
coordinates as search probes: the two split fragments of the
glycine-bound GluN1 LBD (Protein Data Bank [PDB] code:
1PB7) (Furukawa and Gouaux, 2003) and the L-glutamate-
bound GluN2A LBD (Furukawa et al., 2005) (PDB code: 2A5S)
containing the upper lobe and the lower lobe of the respective
clamshell-like structures. With the improved crystals and data
sets, we were able to acquire clear electron density for 565 res-
idues out of 575 possible residues for GluN1/GluN2A LBD-gly/
glu, 22 more residues than the previous GluN1/GluN2A LBD-
gly/glu structure (Furukawa et al., 2005). The newly resolved
regions of the structure included the motifs, Loop1 and Loop2
in GluN1, the hinge loop of the bilobed structure in GluN2A,
the N-terminal ends in GluN1 LBD and GluN2A LBD, and the
C-terminal end of GluN1 LBD. For GluN1/GluN2A LBD-gly/D-
AP5, GluN1/GluN2A LBD-gly/PPDA, and GluN1/GluN2A LBD-
DCKA/glu structures, electron density for 545, 556, and 554 res-
idues out of 575 possible residues were observed, respectively.
Overall Architecture and Antagonist Binding Site
The high resolution crystallography (1.85 A˚–2.1 A˚) conducted in
this study led to unambiguous identification of antagonist bind-
ing sites as well as detailed understanding of the ligand-binding
modes and the pattern of overall protein conformational alter-
ations. Both GluN1 and GluN2A LBDs have bilobed clamshell-
like structures composed of upper (D1) and lower (D2) domains
(Figure 2). All of the NMDA receptor subunits contain three pairs
of disulfide bonds, one located in the lower lobe and the other368 Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc.two located in the Loop 1 motif, which is specific to NMDA
receptors (Figure 2) (Furukawa and Gouaux, 2003; Furukawa
et al., 2005). The ligand binding sites are located at the inter-
D1-D2 cleft in both GluN1 and GluN2A but with strict specificity
for glycine and DCKA in GluN1 and L-glutamate, D-AP5, and
PPDA in GluN2A (Figure 2A). Even though the crystals for
GluN1/GluN2A LBD in complex with glycine and L-glutamate
were grown in the different condition from the previous one
(Furukawa et al., 2005), the modes of glycine and L-glutamate
binding as well as the overall structure is close to identical with
root-mean-square deviation (rmsd) of 0.44 A˚ over 543 Ca posi-
tions (Figure S1). In all of the four crystal structures with different
ligands bound, the GluN1 and GluN2A LBDs are assembled
as heterodimers in the back-to-back arrangement where the
GluN1 and GluN2A ligand-binding sites are facing away from
each other (Figure 2). However, the overall conformations of
the GluN1/GluN2A LBD structures in different ligand combina-
tions are highly distinct from one another as described in the later
section.
Antagonist Binding in GluN1/GluN2A LBD
The current crystallographic study provides high quality electron
density, which shows the exact positions of ligands as well as
amino acid residues and water molecules involved in compound
recognition. In GluN2A, binding of both D-AP5 and PPDA occur
at the inter-D1-D2 cleft in the bilobed clamshell-like structure of
GluN2A but through different chemistry. In general, D-AP5 binds
to GluN2Amostly via polar interactions involving similar residues
to those participating in L-glutamate binding (Figures 3A, 3B,
3D, and 3E). Residues from D1 including Ser511, Thr513, and
Arg518 form polar interactions with the a-carboxylate and
a-amino groups of D-AP5 whereas His484 ‘‘caps’’ the entire
Neuron
Structures of Antagonist-Bound NMDA Receptorsamino group through van derWaals interaction. Binding residues
in D2 are similar between the L-glutamate-bound and the
D-AP5-bound structures, however, the placement of the bulky
phosphono group in D-AP5 pushes and rearranges the orienta-
tion of the D2 residues by forming direct and water-mediated
polar interactions with them. The phosphono group is ‘‘locked’’
by seven polar interactions mediated directly by Ser689,
Thr690, and Tyr730 and indirectly by Val685, Pro686, Gly688,
and Glu691 via water (W2 and W3; Figures 3B and 3E).
The crystallographic study on GluN1/GluN2A LBD-PPDA pro-
vides important insights into stereoselectivity and ligand recog-
nition. First, ()-(2S, 3R)-PPDA (()-PPDA) has a preferential
binding over (+)-(2R, 3S)-PPDA ((+)-PPDA). The crystal structure
clearly shows exclusive binding of the ()-PPDA enantiomer
even though the crystals were soaked against a buffer contain-
ing a racemic mixture of (+)-PPDA and ()-PPDA (Figure 4A).
In the previous study, only the ()-PPDA enantiomer has been
tested and shown to inhibit NMDA receptors (Feng et al.,
2004). Thus, to understand whether or not ()-PPDA is the
only inhibitory component in the racemic mixture, we have syn-
thesized individual enantiomers and tested them for their ability
to inhibit the GluN1/GluN2A and GluN1/GluN2D NMDA receptor
currents using two electrode voltage clamp (TEVC) on Xenopus
oocytes injected with cRNAs encoding rat NMDA receptor sub-
units. Measurement of dose-response inhibition by (+)-PPDA
and ()-PPDA shows that both enantiomers can inhibit GluN1/
GluN2A and GluN1/GluN2D NMDA receptors, however, with
6- to 7-fold weaker potency for (+)-PPDA than ()-PPDA (Fig-
ure 4B). Both enantiomers have 5- to 6-fold higher potency to-
ward GluN1/GluN2D than GluN1/GluN2A indicating that (+) and
() enantiomers have a similar degree of specificity toward
GluN2D over GluN2A (Figure 4B; Table S2). The second impor-
tant observation is that binding of ()-PPDA involves distinct
residues and chemistry from D-AP5 except for the conserved
polar interactions between the amino group moiety (the nitrogen
at the 4-position and the carboxylate group at the 3-position of
piperazine ring) and Thr513 and Arg518 (Figures 3C, 3F, and
4A). The majority of the binding is mediated by hydrophobic
interactions involving the phenanthrene rings of ()-PPDA,
which are oriented toward the hydrophobic core of the
GluN2A LBD around Helix H by the piperazine ring stabilized
in the chair configuration (Figure 3C). Consequently, the phen-
anthrene rings are surrounded by clusters of hydrophobic resi-
dues including Phe416, Val713, Val734, and Tyr737 and the
methylene group of Lys738 whose ε-NH3
+ is salt bridged to
Glu714 and, thus, is capable of forming hydrophobic interaction
(Dyson et al., 2006) (Figures 3C and 3F; residues with green
background).
The crystal structure of GluN1/GluN2A LBD in complex with
DCKA/L-glutamate shows the antagonist-bound GluN1 LBD in
the context of GluN1-GluN2A heterodimer. The GluN1 LBD
portion of the GluN1/GluN2A LBD-DCKA/glu structure is highly
similar to the monomeric GluN1 LBD-DCKA structure (Furukawa
andGouaux, 2003) with rmsd of 0.91 A˚ over 274Capositions and
0.55 A˚ over 266 Ca positions for protomer A and B, respectively,
even though their crystallization conditions are highly distinct
from one another (Figure S2). Furthermore, the pattern of
DCKA binding at the ligand-binding site, including the water-mediated polar interaction, is identical between those two struc-
tures (Figure S2). Thus, the overall protein conformation of the
GluN1 LBD-DCKA and the chemistry for ligand recognition of
DCKA appear to follow the strict rule regardless of crystallization
conditions or of the presence or absence of GluN2A LBD. The
above observation could also imply that known cooperativity be-
tween the glycine binding site inGluN1 and the L-glutamate bind-
ing site in GluN2 (Mayer et al., 1989; Regalado et al., 2001) may
not occur through the GluN1-GluN2A heterodimer interface
present in the current crystal structures. Instead, the possible
GluN1-GluN2 interaction sites that mediate the glycine-L-gluta-
mate binding cooperativity may involve the interfaces between
the two LBD heterodimers or plausible interfaces between LBD
and either ATD or TMD in the context of the heterotetrameric
subunit assembly. Thus, understanding the structure-based
mechanism of glycine-L-glutamate binding cooperativity would
likely require a structure of the intact heterotetrameric NMDA
receptor.
Mutational Analysis of GluN2A Antagonist Binding Site
Inspection of the ligand-binding site clearly shows distinct bind-
ing modes between D-AP5 and ()-PPDA involving different
structural elements in theGluN2A ligand-binding site. To validate
the physiological relevance of the structural observation and to
further characterize the chemical nature of the ligand binding
site, we carried out mutational analysis of residues involved in
antagonist binding by measuring current inhibition by TEVC.
Mutagenesis on Phe416, Val713, Tyr730, Val734, Tyr737, and
Lys738 affected sensitivity to L-glutamate, whereas that on
Ser689 or Thr690 completely abolished a response to L-gluta-
mate. Thus, normalized potency of D-AP5 and ()-PPDA were
calculated by determining EC50 values of L-glutamate and IC50
values for D-AP5 and ()-PPDA at fixed L-glutamate concentra-
tions and by converting EC50 and IC50 into Ki values using the
Cheng-Prusoff equation (Cheng and Prusoff, 1973) for each of
the tested mutants (Figure 5; Table S3).
The mutational analysis indeed verifies the involvement of
distinct residues in binding of D-AP5 and ()-PPDA and thus,
validates the physiological relevance of the crystal structures ob-
tained in this study. In general, mutation of residues surrounding
the phenanthrene rings of ()-PPDA (Figure 3F; residues in
emerald green background) affects potency of ()-PPDA with
little or no effect on potency of D-AP5. Among those mutations,
GluN2A Val734Ala, Tyr737Ala, and Lys738Met, have significant
effects on the ()-PPDA potency but with only minor effects on
the D-AP5 potency (Figures 5C and 5D). An intriguing observa-
tion is that while Val734Ala and Tyr737Ala both decreases
the ()-PPDA sensitivity by reduction of van der Waals inter-
action with the phenanthrene ring, Lys738Met increases the
()-PPDA sensitivity by strengthening the interaction likely
through aromatic-sulfur interaction (Zauhar et al., 2000). Among
GluN2s, GluN2A is the only subunit with lysine in the 738 position
whereas the other three subunits (GluN2B–D) contain methio-
nine at this position. Consistently, GluN1/GluN2A NMDA recep-
tor is the subtype that is least sensitive to ()-PPDA (Feng et al.,
2004). Thus, we propose that the preferential binding of
()-PPDA toward GluN2B/C/D over GluN2A containing NMDA
receptors derives from different modes of interaction with theNeuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc. 369
Figure 3. Antagonist Binding in GluN2A LBD
(A–C) Stereoview of the ligand binding sites located at the D1-D2 interface. Binding of L-glutamate (green sticks; A), the GluN2 antagonists involve residues from
both D1 and D2 for both D-AP5 (cyan sticks; B), and PPDA (yellow sticks; C). Dashed lines represent polar interactions. The current crystallographic study shows
unambiguous electron density of L-glutamate (A), D-AP5 (B), and PPDA (C) as well as critical water molecules for binding (red spheres; W1–3). The electron
density (blue mesh) represents the Fo-Fc omit map contoured at 3s.
(legend continued on next page)
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Figure 4. GluN1/GluN2A NMDA Receptors
Selectively Bind (–)-PPDA over (+)-PPDA
(A) Enantiomers of PPDA showing two chiral cen-
ters (stars) at the 2 and3positions of the piperazine
ring. PPDA used in this crystallographic study is
the enantiomeric mixture available commercially
(TOCRIS). However, the electron density indicates
the exclusive presence of ()-(2S, 3R)-PPDA as
shown in Figure 3C.
(B) Inhibition of glycine/L-glutamate ion channel
current by (+)-(2S, 3R)-PPDA (filled circle) or
()-(2S, 3R)-PPDA (square) in the GluN1-1a/
GluN2ANMDA receptors. The currents are formed
by coapplication of 100 mM of glycine and 5 mM of
L-glutamate and inhibited by various concentra-
tions of PPDA. All of the recordings are done using
the TEVC method. Error bars represent SD.
See also Table S3.
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Structures of Antagonist-Bound NMDA Receptorsphenanthrene ring at the 738 position. Mutations on other resi-
dues surrounding the phenanthrene ring, Phe416Ala and
Val713Ala, have minor effects on sensitivity to both ()-PPDA
and D-AP5, consistent with the structural observation that those
residues are further away from the phenanthrene ring compared
to Val734, Tyr737, or Lys738, and therefore not at the ideal
position to form a strong van der Waals interaction. Tyr730
participates in binding of D-AP5 through polar interaction with
the phosphono group and, to a minor extent, of ()-PPDA
through van der Waals interaction with the piperazine ring. The
Tyr730Phe mutation results in a 5-fold decrease in sensitivity
of D-AP5 by reduction in number of polar interactions whereas
it results in an increase in ()-PPDA sensitivity perhaps by
strengthening of hydrophobic interactions due to absence of
hydroxyl group (Figure 5C and 5D).
Binding Specificity in NMDA Receptors and Non-NMDA
Receptors
Specific inhibition of NMDA-induced currents by antagonists
was crucial in confirming the existence of the iGluRs (Watkins
and Evans, 1981). D-AP5 was one of the first antagonists
discovered to specifically inhibit NMDA-induced current while
()-PPDA was later reported to inhibit NMDA receptors with
subtype specificity toward GluN2C/GluN2D containing NMDA
receptors (Feng et al., 2004). Structural comparison between
GluN1/GluN2A LBD and non-NMDA receptor LBDs show ele-
ments that may play a role in distinguishing NMDA receptors
and non-NMDA receptors such as AMPA and kainate receptors.
The residues from D1 in direct contact with or in vicinity of D-AP5
are mostly conserved in non-NMDA receptors except that the
equivalent residue to GluN2A His484 is tyrosine in AMPA and
kainate receptors (Figures 6A and 6B). As described above,
direct and indirect polar interactions in D2 are mediated by
side chains of Ser689, Thr690, and Tyr730, and nitrogen and(D–F) Schematic representation of L-glutamate (D), D-AP5 (E), and ()-PPDA (
analyzed by LIGPLOT v.4.5.3 (Wallace et al., 1995). Dotted lines represent polar i
Red spheres marked by ‘‘W’’ represent water molecules at the binding sites. Res
magenta (from D2) backgrounds. Residues uniquely involved in binding of ()
are different between the L-glutamate-bound, the D-AP5-bound, and the ()-PPD
See also Figures S1, S2, and S5.oxygen atoms from the main chain. While GluN2A Ser689 and
Thr690 are conserved in all of the L-glutamate binding subunits
in iGluRs, Tyr730 is unique to the GluN2 subunits in NMDA
receptor family (Figure 6C). The equivalent residues of GluN2A
Tyr730 are GluA2 Leu704 and GluK1 Met722, which cannot
form direct polar interaction or ‘‘cap’’ the binding site as GluN2A
Tyr730 does. Consistent with the structural and primary
sequence analyses, mutating GluN2A Tyr730 to leucine or
methionine dramatically reduces D-AP5 sensitivity (20-fold
and 80-fold increase in Ki values in Tyr730Leu and Tyr730Met,
respectively) while it causes little or no change in sensitivity to
()-PPDA. However, mutating GluA2 Leu704 and GluK1
Met722 to tyrosine does not confer sensitivity to D-AP5 in those
non-NMDA receptors, indicating that specific binding of D-AP5
to NMDA receptors is not determined solely by the tyrosine res-
idue in the binding pocket (data not shown). Overall, Tyr730 is a
critical but not the only factor that facilitates specific inhibition of
NMDA receptor by D-AP5.
In contrast to D-AP5, the structural comparison between
GluN1/GluN2A LBD andGluA2 or GluK1 LBD shows no apparent
molecular features that may interfere with binding of ()-PPDA
in non-NMDA receptors, but instead, points out a reasonable
possibility of ()-PPDA binding to occur (Figures 7A and 7B).
To validate this structural observation, we assessed the inhibi-
tion pattern of ()-PPDA on L-glutamate-induced currents
produced by nondesensitizing mutants of GluA2 Leu483Tyr
flip (Stern-Bach et al., 1998) and GluK1 Tyr506Cys Leu768Cys
(Weston et al., 2006) using TEVC. The application of 100 mM
()-PPDA in the presence of agonists completely inhibited not
only GluN1/GluN2A NMDA receptors, but also GluA2 AMPA
receptors and GluK1 kainate receptors (Figure 7C). Indeed,
both GluA2 and GluK1 respond to ()-PPDA with Ki values of
7.85 mM and 1.17 mM, respectively, which are comparable to
Ki of 0.82 mM in GluN1/GluN2A receptors (Table S3). TheseF) binding sites. The crystal structures around the ligand binding sites were
nteractions whereas red arcs with spokes represent hydrophobic interactions.
idues involved in binding of L-glutamate and/or D-AP5 have blue (from D1) and
-PPDA have an emerald green background. Orientations of the D2 residues
A-bound GluN2A LBDs due to a large domain movement of D2 relative to D1.
Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc. 371
Figure 5. Mutagenesis of the Ligand-
Binding Site
Residues surrounding the antagonist binding site
are mutated and tested for inhibition of ion channel
activities to validate physiological relevance of the
crystal structures.
(A) Typical dose-response inhibition pattern of the
wild-type GluN1/GluN2A NMDA receptor current
assessed by TEVC. In this recording, currents
formed by application of 100 mM of glycine and
5 mM L-glutamate are inhibited by various con-
centrations of D-AP5 (top) or ()-PPDA (bottom).
Note that there is no significant rundown of
currents before and after the dose-response
experiment.
(B) All of the data points can be fit to a one-binding-
site model of Hill equation.
(C and D) Fold increase of Ki values for D-AP5 (C)
and ()-PPDA (D). Ki values were calculated by
the Cheng-Prusoff equation using EC50 values for
L-glutamate and IC50 values for the antagonists for
every mutant.
See also Table S3.
Neuron
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zine-2,3-dicarboxylate derivatives can act on both kainate and
NMDA receptors (Irvine et al., 2012). The current study clearly
shows that ()-PPDA is a general antagonist that acts on all
of the L-glutamate-binding iGluR subunits. A recent study has
shown that the Tyr506Cys/Leu768Cys mutations in GluK1 re-
ceptors desynchronize receptor activation (Dawe et al., 2013).
However, the overall interpretation that ()-PPDA acts on
GluK1 receptors with comparable potency to the GluN1/GluN2A
NMDA receptors should remain intact.
Antagonist-Mediated Conformational Change in GluN1/
GluN2A LBD
Extensive studies on non-NMDA receptor LBDs and the crystal
structure of the intact GluA2 receptors demonstrated that LBDs
form 2-fold symmetric homodimers that further assemble into
tetramers corroborating with the idea that the basic functional
unit in iGluRs is a dimer (Mayer, 2011; Sobolevsky et al.,
2009). In the GluA2 and GluK1 LBDs, conformational alteration
of the bilobed structures were observed in a way that agonist-
bound and antagonist-bound structures were stabilized in
closed and open conformations, respectively (Mayer et al.,
2006; Sun et al., 2002). Furthermore, in GluA2, apo state is
stabilized in the open cleft conformation similar to the anta-372 Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc.gonist-bound structure (Armstrong and
Gouaux, 2000). This ligand-dependent
conformational variation results in
changes in the distances between the
linkers adjacent to the transmembrane
ion channel domains (defined as Ile633
in GluA2 and Ile653 in GluK1) in the
dimer pairs of GluK1 and GluA2 LBDs
where agonist binding separates the
linker distances. The linker movement
resulting from the conformational alter-ation of the LBDs has been suggested to be coupled, at least
in part, to a gating event in the ion channel (Mayer et al.,
2006; Sun et al., 2002).
The current study structurally demonstrates the pattern of
conformational alterations in NMDA receptors in the context of
the GluN1/GluN2A heterodimer. In NMDA receptors, GluN1
LBD has been shown to be stabilized in open-cleft conforma-
tions in the presence of antagonists, DCKA (Furukawa and
Gouaux, 2003) and cycloleucine (Inanobe et al., 2005), or in the
apo-state (Yao et al., 2013). The structure of GluN1/GluN2A
LBD in complex with the GluN1 antagonist, DCKA, and L-gluta-
mate shows that theGluN1 LBD is in the open-cleft conformation
similar to the one observed in protomer A in the previous study
on GluN1 LBD-DCKA (Furukawa and Gouaux, 2003) (Figure S3).
Compared to the glycine/L-glutamate-bound GluN1/GluN2A
LBD structure, the DCKA/L-glutamate-bound structure has
26 opening in the GluN1 LBD cleft while little or no change
is observed in the pattern of the GluN1-GluN2A heterodimeric
arrangement or in the conformation of GluN2A LBD (rmsd =
0.51 A˚ over 277 Ca positions within GluN2A LBD) (Figure S3).
The structures of GluN1/GluN2A LBD in complex with glycine/
D-AP5 or with glycine/()-PPDA show opening of the GluN2A
LBD structure, however, to different extents. Binding of D-AP5
and ()-PPDA results in opening of the bilobed structure of the
Figure 6. Comparison of GluN2A LBD and
Non-NMDA Receptor LBDs
(A and B) Superposition of GluA2 (A) and GluK1 (B)
LBDs onto the GluN2A LBD-D-AP5 structure. The
LBD structures of GluA2 (PDB code: 1FTL) and
GluK1 (PDB code: 2F34) are split into D1 and D2
domains and superposed onto the respective
domains of GluN2A LBD-D-AP5 structure by the
program LSQKAB (Kabsch, 1976). The GluN2A
residues involved in binding of D-AP5 are shown
in blue sticks whereas D-AP5 is shown in yellow
sticks. Side chains of non-NMDA receptor resi-
dues that are involved in ligand-binding and are
different from GluN2 subunits are shown in gray
(GluA2) and green (GluK1). A notable difference is
found at the position of GluN2A Tyr730 (arrows)
where the equivalent residues in GluA2 and
GluK1 are Leu704 (gray sticks) and Met722 (green
sticks), respectively.
(C) Sequence alignment of the glutamate binding
iGluR subunits around GluN2A Tyr730 (arrow).
Tyrosine is conserved in the NMDA subfamily
(blue) whereas the equivalent residue in the AMPA
(black) and kainate (green) subfamilies is either
leucine or methionine.
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Structures of Antagonist-Bound NMDA ReceptorsGluN2A LBD by 14.4 and 19.4, respectively, compared to the
L-glutamate-bound form while it causes little or no change in
the GluN1-GluN2A subunit arrangement and the GluN1 confor-
mation (rmsd = 0.48 A˚ for D-AP5 and 0.62 A˚ for ()-PPDA over
282 Ca positions; Figures 8A and 8B). Opening of the GluN2A
LBD cleft is mediated throughmovement of D2 (lower lobe) while
D1 is locked by intersubunit interactions in the GluN1/GluN2A
LBD heterodimers. Stabilization of the open cleft conformation
of GluN2A LBD by D-AP5 and ()-PPDA occurs through distinct
mechanisms involving discrete elements of the ligand binding
site. In the D-AP5-bound form, movement of Helix E caused by
the placement of the phosphono group appears to be the driving
force for the opening of the bilobed structure whereas in the
()-PPDA-bound form, movement of Helix G and H by the place-
ment of the bulky phenanthrene group may be the cause of the
cleft opening (Figure 8A; arrows). Consistently, there is no direct
contact between D-AP5 and Helix G and H whereas there is only
one contact between ()-PPDA and Helix E. The cleft opening by
bothD-AP5 and ()-PPDA ismediated through rigid-bodymove-
ment of D2 (rmsd = 0.39 A˚ over 101 Ca positions in D2 between
D-AP5-bound and ()-PPDA-bound structures) despite different
modes of ligand-receptor interactions causing such conforma-
tional change.
The GluN1/GluN2A LBD structures in the various ligand
combinations reveal the movement of the linkers leading to the
transmembrane ion channel. Binding of antagonists results inNeuron 81, 366–378shortening of the linker distances (defined
as Ile664 in GluN1 and Val662 in GluN2A)
in the GluN1-GluN2A heterodimer pairs.
The differences in the linker distances in
comparison with the glycine/L-gluta-
mate-bound form (D-linker-distance) are
6.4 A˚, 4.3 A˚, and 4.3 A˚ for the DCKA/L-glutamate, glycine/D-AP5, and glycine/()-PPDA forms, respec-
tively, (Figures 8C and 8D). The5 difference in the ‘‘openness’’
of the bilobed structures between GluN2A-D-AP5 and GluN2A-
()-PPDA does not alter the location of GluN2A Val662, thus,
the GluN1-GluN2A D-linker-distance of the glycine/D-AP5 is
similar to that of the glycine/()-PPDA forms. Overall, D-linker-
distances are minor compared to those observed in the homodi-
meric non-NMDA receptor LBDs (Figure 8D) because the NMDA
receptor antagonists only bind to either GluN1 or GluN2A in the
heterodimeric GluN1/GluN2A LBDs whereas non-NMDA recep-
tor antagonists bind to both subunits in the homodimeric non-
NMDA receptor LBDs. The above observation implies that
even a small perturbation of the LBD-TMD linker may be suffi-
cient to cause inhibition in NMDA receptors. Superposition
of the D-AP5- or ()-PPDA-bound GluN2A LBD structure onto
the GluN1/GluN2A LBD-DCKA/L-glutamate structure shows
the plausible state where LBDs from both subunits are occupied
with antagonists. In those cases, D-linker-distances are calcu-
lated to be 12 A˚ and 13 A˚, which are comparable to the distance
observed in the non-NMDA receptors (Figure 8D). Despite exten-
sive efforts we have been unable to obtain a structure of GluN1/
GluN2A LBD in complex with DCKA and D-AP5 or ()-PPDA.
How could the conformational alterations in LBDs change
positioning of linkers in the context of the tetrameric arrange-
ment in NMDA receptors? To speculate on this question, we
have constructed the heterotetrameric model of NMDA, January 22, 2014 ª2014 Elsevier Inc. 373
Figure 7. (–)-PPDA Binding on GluN2A LBD
and Non-NMDA Receptor LBDs
(A and B) Superposition of GluA2 (A) and GluK1
LBDs (B) onto the GluN2A LBD-()-PPDA struc-
ture. The structural superposition is done in the
same manner as in Figure 6. Side chains of non-
NMDA receptor residues that are involved in
ligand-binding and are different from GluN2 sub-
units are shown in gray (GluA2) and green (GluK1).
In both GluA2 and GluK1 receptors, there appear
to be no residue that may prevent ()-PPDA from
binding.
(C) ()-PPDA can robustly inhibit currents pro-
duced by GluN1-1a/GluN2A NMDA receptors,
GluA2 AMPA receptors (Leu483Tyr, flip), and
GluK1 kainate receptors (Tyr506Cys Leu768Cys).
Here, NMDA receptor and non-NMDA receptor
currents are induced by 100 mM glycine/30 mM
glutamate and 30 mM glutamate, respectively, and
inhibited by application of 100 mM ()-PPDA in the
presence of agonists. All of the recordings were
done using TEVC on Xenopus oocytes injected
with cRNAs encoding GluN1/GluN2A NMDA
receptor, GluA2 AMPA receptor mutant, and
GluK1 kainate receptor mutant. The Ki values for
()-PPDA inhibition are 7.85 mM and 1.17 mM for
GluA2 (flip, Leu483Tyr) and GluK1 (Tyr506Cys
Leu768Cys), respectively.
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onto the intact tetrameric GluA2 AMPA receptor (Sobolevsky
et al., 2009) based on the assumptions that the tetrameric sub-
unit arrangement is similar between NMDA receptors and
AMPA receptorswithin LBD and that theGluN1 andGluN2A sub-
units are arranged in the 1-2-1-2 format as suggested recently
(Riou et al., 2012; Sobolevsky et al., 2009) (Figure S4). The heter-
otetrameric models bound to different ligands show that the
areas of tetragon definedby the four linkers (spheres in Figure S4)
as vertices in the antagonist-bound forms are consistently
smaller compared to the equivalently defined area in the
glycine/L-glutamate-bound form. Even though this observation
is highly speculative, the models suggest that changes in the
linker positioning in the tetrameric subunit arrangement may be
correlated to opening and closing of the ion channels.
DISCUSSION
In this study, we show structural representations of competitive
antagonism of NMDA receptors in the context of the heterodi-
meric GluN1/GluN2A LBDs. This has been achieved by obtaining
the crystal structures of GluN1/GluN2A LBDs bound to compet-
itive GluN2 antagonists, D-AP5 and ()-PPDA, and a competi-
tive GluN1 antagonist, DCKA. Overall, these antagonist-bound
GluN1/GluN2A LBD structures along with the agonist-bound
GluN1/GluN2A LBD structure provide important insights into
the pharmacology of antagonist binding as well as the pattern
of ligand-induced conformational movements that may be
coupled to regulation of the ion channel activity.374 Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc.Obtaining the crystal structures of the GluN2 subunit in com-
plex with antagonists required a rather unexpected technical
tweak involving soaking of the GluN1/GluN2A LBD crystals in
complex with glycine and L-glutamate against the crystallization
buffers containing antagonists. The GluN1/GluN2A LBD crystals
grown in the condition accommodated large conformational
changes caused by binding of antagonists with substantial
changes in cell unit dimensions (Table S1). The experimental
outcome is valid for the following reasons: (1) a series of struc-
ture-based mutagenesis at the antagonist binding site coupled
to the electrophysiological experiments strongly shows the
physiological relevance of the ligand-binding modes (Figure 5),
and (2) the DCKA-bound GluN1/GluN2A LBD heterodimer struc-
ture in the current study has a very similar open conformation
in the GluN1 to the one previously observed in the GluN1 LBD-
DCKA structure derived from crystals grown in a different condi-
tion (Furukawa and Gouaux, 2003) (Figures S2 and S3). Taken
together, the soaking method implemented here can now serve
as an excellent crystallographic tool to visualize binding modes
of NMDA receptor compounds and support structure-based
drug design to move forward.
The crystal structures and structure-based mutagenesis pro-
vide structural elements in the binding pocket, which are crucial
for specific binding of compounds to NMDA receptors (versus
non-NMDA receptors) and NMDA receptor subtypes (GluN2A–
GluN2D). On the one hand, the difference between NMDA
receptors and non-NMDA receptors is marked by GluN2A
Tyr730, which is uniquely present in all of the NMDA receptor
GluN2 subunits and forms polar interaction with the phosphono
Figure 8. Binding of D-AP5 and (–)-PPDA
Induce Different Degreed of Domain
Movement
(A) Superposition of GluN1/GluN2A LBD struc-
tures in complex with L-glutamate (green), D-AP5
(yellow), and ()-PPDA (cyan). The Cas of D1
in GluN2A in D-AP5-bound or ()-PPDA-bound
forms and L-glutamate-bound form are super-
posed to observe the differences in the extent of
domain opening caused by the GluN2-antagonist
binding. D-AP5 and ()-PPDA induce opening of
the clamshell-like architecture through mobiliza-
tion of Helix E and Helix G, respectively. Spheres
at the bottom of the structures represent Ca of
GluN2A Val662 next to the M3 transmembrane
region. GluN1 LBD is omitted from this figure for
clarity.
(B) Analysis of domain opening of antagonist-
bound LBD structures relative to the L-glutamate-
bound LBD structures in GluA2 (PDB code: 1FTJ
for L-glutamate versus 1FTL for DNQX), GluK1
(PDB code: 2F36 for L-glutamate versus 2F34 for
UBP310) GluN1, and GluN2A. The rotation angles
are measured using the program Dyndom (Hay-
ward and Lee, 2002). Below the bar graph is
the schematic presentation of domain opening
resulting from binding of an antagonist.
(C) The same superposition as (A) but showing
GluN1 LBD in complex with glycine (light gray)
viewed from the side (top) and from the bottom or
the membrane plane (bottom). Spheres in GluN1
represent Ca of Ile664. Dashed lines show dis-
tances between GluN1 Ile664 and GluN2A Val662,
which are plausible measures of the TMD move-
ment. The linker distance for GluN1/GluN2A LBD-
gly/glu is shown in red whereas that for GluN1/
GluN2A LBD-gly/D-AP5 or GluN1/GluN2A LBD-
gly/PPDA is in black.
(D) Differences in the GluN1 Ile664-GluN2A Val662
distances between antagonist-bound (black dash
in C) and the agonist-bound (glycine and L-gluta-
mate; red dash in C) structures (D-linker-dis-
tances). The interlinker distances in the DCKA/
PPDA and DCKA/D-AP5 forms (asterisks) are calculated using hypothetical models built by superposing the D1 of the DCKA/glu-bound GluN1/GluN2A LBD onto
that of GluN1/GluN2A LBD structures bound to gly/D-AP5 or gly/()-PPDA. In GluA2, distances between the Cas of Ile663 in the GluA2 LBD homodimers in the
L-glutamate-bound (PDB code: 1FTJ) and DNQX-bound (PDB code: 1FTL) forms are measured. In GluK1, distances between the Cas of Ile653 in the GluK1 LBD
homodimers in L-glutamate-bound (PDB code: 2F36) and UBP310-bound (PDB code: 2F34) forms are measured. Below the bar graph is the schematic
presentation to show that the antagonist-induced domain opening of LBD may result in a decrease in the interlinker distance (arrows between two spheres),
thereby causing the transmembrane ion channel to close.
See also Figures S3 and S4.
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Structures of Antagonist-Bound NMDA Receptorsgroup of D-AP5 (Figures 3B and 6). Indeed, D-AP5 is highly
specific to NMDA receptors with no inhibitory effect as high
as 100 mM, which clearly explains why Watkins and colleagues
were able to distinguish the NMDA-induced currents from
others (Davies and Watkins, 1982). On the other hand, the
structural elements that control subtype-specific binding of
GluN2-targeting antagonists lie in the hydrophobic pocket that
extends from the core of the L-glutamate binding site where
the phenanthrene ring in ()-PPDA is located (Figure 3F;
emerald green background). Among all the residues in the hy-
drophobic pocket, Lys738 is unique to GluN2A and is methio-
nine in all the other NMDA receptor subunits (GluN2B–GluN2D)
at the equivalent position. Thus, taking all the above informationtogether, we speculate that a compound harboring a phos-
phono group that mediates interaction with GluN2A Tyr730
and a substituted phenanthrene-like moiety that extends
toward the hydrophobic pocket (Figure 3F; emerald green
background) and promotes interactions with GluN2A K738 but
disfavors interactions with methionine side chains present in
GluN2B–GluN2D would specifically inhibit GluN2A containing
NMDA receptors with no cross-effects on non-NMDA recep-
tors. In this regard, NVP-AAM077 and SDZ220-040 (Figure S5),
which contain a phosphono group similar to D-AP5 (light orange
background in Figure S5) and aromatic rings that may extend
toward the hydrophobic pocket (light green background in Fig-
ures 3F and S5) with nanomolar potency (Frizelle et al., 2006;Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc. 375
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compounds for development of a subtype-specific competitive
inhibitor for NMDA receptors. NVP-AAM077 has been previ-
ously shown to have 5-fold specificity toward the GluN2A con-
taining NMDA receptors over the GluN2B containing NMDA
receptors (Frizelle et al., 2006). It would be important to obtain
crystal structures of GluN1/GluN2A LBDs in complex with NVP-
AAM077 and SDZ220-040 to visualize how the aromatic groups
are oriented in the hydrophobic pocket (Figures 3C and 3F) and
understand how to modify the design of the aromatic groups
to promote interaction with GluN2A K738 and gain GluN2A-
specificity.
Our crystallographic study shows that the binding of D-AP5
and ()-PPDA both stabilize the open cleft conformation of the
bilobed architecture of GluN2A LBD compared to the L-gluta-
mate-bound form despite the substantial difference in binding
modes. The current study shows that the GluN2 LBD undergoes
a similar pattern of ligand-induced conformational changes
to glycine-binding GluN1 LBD and non-NMDA receptor LBDs
(Armstrong and Gouaux, 2000; Furukawa and Gouaux, 2003;
Mayer, 2005; Mayer et al., 2006). Of importance to note is the
observation that the extent of opening in the GluN2A LBD
conformation is significantly different between the D-AP5-bound
form (14.4) and the ()-PPDA-bound form (19.4), however, the
potency of inhibition is similar to each other implying that the
degree of domain opening may not be correlated to effective-
ness of the antagonist activity.
The ligand-induced opening and closing of the LBD bilobes
alters the distances between the linkers that are tethered
to TMD1 and TMD3 of the ion channel in the GluN1-GluN2A
heterodimer pair (Figure 8). In GluA2 AMPA receptor and
GluK1 kainate receptor LBD homodimers, the differences in
linker distances are as large as 8 A˚ to 20 A˚ between the
agonist-bound state and the antagonist-bound state or the apo
state (Mayer et al., 2006; Sun et al., 2002). This conformational
movement has been proposed to be coupled, at least in part,
to ligand-gating of the ion channels. The LBD crystal structures
presented in this study are GluN1/GluN2A heterodimers contain-
ing glycine/D-AP5, glycine/()-PPDA, and DCKA/ L-glutamate,
which uniquely represent the functional state where the activity
of NMDA receptors is inhibited by an antagonist bound to one
subunit while the other subunit contains an agonist. In such
structures, the D-linker-distance is small especially in the case
of glycine/D-AP5 and glycine/()-PPDA (4.3 A˚). This structural
observation is somewhat consistent with the recent findings
that constraining LBD-TMD linkers dramatically reduces open
probability (Kazi et al., 2013; Talukder andWollmuth, 2011). Pre-
cise correlation between the linker movement and the inhibition
potency in NMDA receptors remains an open question.
EXPERIMENTAL PROCEDURES
Institutional Approval
All experiments were conducted using protocols approved by the Cold Spring
Harbor Laboratory Animal Care and Use Committees.
Expression and Purification of GluN1 and GluN2A LBDs
GluN2A LBD was expressed as a fusion protein to small ubiquitin-like modifier
(SUMO). This construct contains a hexa-histidine tag at the N terminus of376 Neuron 81, 366–378, January 22, 2014 ª2014 Elsevier Inc.SUMO followed by LBD in the pET22b vector. The SUMO-GluN2A LBD pro-
teins were expressed in OrigamiB (DE3) cells (Novagen) as described previ-
ously (Vance et al., 2011). The cell lysate was subjected to a Nickel-NTA
Chelating Sepharose chromatography, followed by digestion by ubiquitin
ligase protease-1 to remove SUMO, Q-Sepharose ion exchange chromatog-
raphy, and SP-Sepharose ion exchange chromatography (GE Healthcare).
The expression method using the SUMO-fusion approach in combination
with the purification scheme above improved the protein yield by at least
2.5-fold compared to the previous method (Furukawa et al., 2005). GluN1
LBD proteins were expressed and purified using the previous method (Furu-
kawa and Gouaux, 2003).
Crystallography
The purified GluN1 and GluN2A LBD proteins were individually concentrated
to 6mg/ml, mixed so that a 1:1 weight ratio was achieved and dialyzed against
a buffer containing 10 mM HEPES-NaOH (pH7.0), 100 mM NaCl, 10 mM
glycine, and 1 mM L-glutamate overnight. The GluN1/GluN2A LBD crystals
were produced by vapor diffusion at 17C in hanging drops containing 2:1 pro-
tein to reservoir solution composed of 18% polyethylene glycol monomethy-
lether 2000 (PEG2000MME), 100 mM HEPES-NaOH (pH 7.0), and 75 mM
NaCl. Antagonist-bound crystals were obtained by soaking the gly/glu crystals
against the reservoir solution supplemented with glycine (10 mM) and either
D-AP5 (1 mM), or PPDA (0.1 mM), or L-glutamate (1 mM) and DCKA (1 mM).
The crystals were soaked against the buffer containing 0.1 mM of antagonists
for 48 hr and transferred to the buffer containing 1 mM of antagonists (0.1 mM
for PPDA). After 48 hr, the crystals were soaked against the same buffer con-
taining 18% glycerol and flash frozen by liquid nitrogen. The X-ray diffraction
data were collected at325 beamline at the National Synchrotron Light Source
at Brookhaven National Laboratory and at the ID23-B beamline at the
Advanced Photon System at the Argonne National Laboratory and processed
using HKL2000 (Otwinowski and Minor, 1997). All of the structures were
determined by molecular replacement using four search probes: GluN1 LBD
Domain1 (Thr396-Gln536/Ser765-Arg794), GluN1 LBD Domain2 (Gly537-
Arg755), GluN2A LBDDomain 1 (Asn404-Glu530/Gly760-His801), andGluN2A
LBD Domain 2 (Thr531-Thr759) made from the GluN1/GluN2A LBD coordinate
(PDB code: 2A5T) (Furukawa et al., 2005) and using the program Phaser
(McCoy et al., 2007). Structural refinement andmodel building were performed
with PHENIX (Adams et al., 2002) and Coot (Emsley and Cowtan, 2004),
respectively.
Electrophysiology
Recombinant GluN1/GluN2A NMDA receptors were expressed by coinjecting
0.01–0.05 ng of the wild-type or mutant rat GluN1 and GluN2A cRNAs at a 1:2
ratio (w/w) into defolliculatedXenopus laevis oocytes. For GluA2 Leu483Tyr flip
and GluK1 Tyr506Cys/Leu768Cys, 1–5 ng of cRNAs were injected per oocyte.
The two-electrode voltage-clamp recordings were performed using agarose-
tipped microelectrodes (0.4–1.0 MU) filled with 3 M KCl at a holding potential
of 60 mV. The bath solution contained 5 mM HEPES, 100 mM NaCl, 0.3 mM
BaCl2, and 10 mM Tricine at pH 7.4 (adjusted with potassium hydroxide
[KOH]). Currents were evoked by applications of 100 mMof glycine and various
concentrations of L-glutamate. For dose-response curves, various concen-
trations of antagonists were applied at a given L-glutamate concentration.
The data were acquired and analyzed by the program Pulse (HEKA). Dose-
response curves were plotted and fitted to calculate EC50 values of L-gluta-
mate and IC50 values of antagonists using the program Kaleida graph (Synergy
Software). Ki values were calculated by Cheng-Prusoff equation: Ki = IC50/(1 +
[L-glutamate]/EC50).
Synthesis of PPDA Enantiomers
Reagents were obtained from Aldrich Chemical and used without further
purification. Optima grade solvents were obtained from Fisher Scientific,
degassed with argon, and purified on a solvent drying system as described
(Pangborn et al., 1996) unless otherwise specified. Dichloromethane (HPLC
grade) and tetrahydrofuran (99%+) were purchased from Aldrich and
dried over 4 A˚ molecular sieves before used. Reactions were performed in
flame-dried glassware under positive Argon pressure with magnetic stirring.
Cold baths were generated as follows: 0C, wet ice/water; 40C, dry
Neuron
Structures of Antagonist-Bound NMDA Receptorsice/CH3CN; 78C, dry ice/acetone. Analytical thin-layer chromatography
(TLC) was carried out on commercial Aldrich aluminum-supported silica gel
plates (thickness: 200 mm) with fluorescent indicator (F-254). Visualization
was accomplished by UV light or stained with 5% phosphomolybdic acid in
ethanol. Column chromatography was performed by the method of Still
et al. (1978) with 32–63 mm silica gel (Woelm). For more details, refer to Sup-
plemental Experimental Procedures.ACCESSION NUMBERS
Coordinates and structure factors for GluN1/GluN2A LBDs complexed
to glycine/L-glutamate, DCKA/L-glutamate, glycine/D-AP5, and glycine/
()-PPDA have been deposited in the Protein Data Bank under accession
codes 4NF8, 4NF4, 4NF5, and 4NF6, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
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